Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This intervention refers to the co-administration of intravenous **crystalloid** fluids (such as normal saline or lactated Ringer's solution) and a prophylactic infusion of **norepinephrine** to prevent hypotension following spinal anesthesia in patients undergoing cesarean section. The protocol, studied at the **General Hospital of Ningxia Medical University** (NCT05690334), evaluates how varying volumes of crystalloid coload (0, 5, or 10 mL/kg) influence the 90% effective dose (ED90) of norepinephrine. Norepinephrine acts as a potent alpha-adrenergic agonist to maintain systemic vascular resistance, while crystalloids provide immediate intravascular volume expansion to counteract the vasodilation induced by spinal anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norepinephrine + crystalloid.